托法替尼
医学
贾纳斯激酶
炎症性肠病
溃疡性结肠炎
肿瘤坏死因子α
耐受性
免疫学
阿达木单抗
细胞因子
克罗恩病
炎症
疾病
内科学
英夫利昔单抗
药理学
不利影响
类风湿性关节炎
作者
Badr Al‐Bawardy,Raina Shivashankar,Deborah D. Proctor
标识
DOI:10.3389/fphar.2021.651415
摘要
Inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn’s disease are chronic, relapsing and remitting disorders of intestinal inflammation with potential systemic manifestations. Despite the availability of current biologics, such as anti-tumor necrosis factor (anti-TNF), anti-integrins, anti-interleukins and small molecules such as tofacitinib, the rates of primary and secondary treatment failure remain high in IBD. This highlights the importance of continued development of new therapeutic targets and modifications of existing ones to improve the treatment response rates and to also improve the safety profile and tolerability of these medications. In this review we will discuss novel treatment target agents including selective janus kinase (JAK) inhibitors, anti-interleukin (IL) (IL-12/IL-23), leukocyte trafficking/migrating inhibitors (such as sphingosine-1-phosphate receptor modulator) and other small molecules currently in development.
科研通智能强力驱动
Strongly Powered by AbleSci AI